Trinity Biotech plc has released its Annual Report for 2024, prepared in accordance with the Companies Act 2014. The report provides a comprehensive overview of the company's business activities, including the development, acquisition, manufacturing, and marketing of diagnostic systems. These systems are used for detecting infectious diseases and measuring various chemistry parameters in biological samples. The company has also outlined its plans to develop biosensor devices and related services, such as a continuous glucose monitoring product. Trinity Biotech operates in approximately 100 countries, utilizing both its sales force and a network of international distributors and strategic partners. The report emphasizes the company's commitment to environmentally responsible practices and its dedication to supporting its customers, employees, and the communities it serves. The full report can be accessed through the link below.